Hedge Fund - Tang Capital Management

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240...

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240...

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240...

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240...

After all, activist hedge funds get most of their earnings from investing in companies and pushing them to provide more shareholder value. These funds and their managers can start off with a statement...

According to a newly-amended 13D filing with the US SEC, Kevin C. Tang's Tang Capital Management owns 6.53 million shares of Heron Therapeutics Inc (NASDAQ:HRTX), the stake amassing 17.4% of the company...

Down 4.8% during ordinary trading hours, shares of Heron suddenly took wing, rising 6.5% in the after-hours market after it was revealed that director and hedge fund manager Kevin Tang had made a series...

Kevin Tang's Tang Capital Partners is one of the funds that have already revealed their equity portfolios as of the end of last year. The healthcare-focused investment firm reported an equity portfolio...

Kevin C. Tang's Tang Capital Management has decreased its position it two pharmaceutical companies. The $200 million hedge fund recently decreased its position in OncoGenex Pharmaceuticals Inc (NASDAQ...